Fragmento

• Susceptibility of clinical strains of Leishmania to pentavalent antimony and miltefosine: challenges and opportunities. • É possível o desenvolvimento de novos medicamentos para as doenças negligenciadas? • Development of new drugs for visceral leishmaniasis. • Program update on a topical paromomycin plus gentamicin formulation (WR279,396) for the treatment of cutaneous leishmaniasis. • Current business models to address research and development for products for neglected diseases. • Implications for developing countries: the good, the bad and the ugly.

Palabras clave:

2013-03-25   |   314 visitas   |   Evalua este artículo 0 valoraciones

Vol. 31 Núm.3. Septiembre 2011 Pags. 192-198 Biomédica 2011; 31(Sup 3, I Tomo)